Genomic sequencing Assessment of 733 HER2-amplified Major and metastatic breast tumours revealed sizeable enrichment of mutations that activate RAS–MAPK signalling in Superior tumours handled with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. By clicking “Accept All Cookies”, you https://www.directivepublications.org/journal-of-clinical-breast-cancer/